Along this review, we presented frontrunner alternatives to combine with these anti-MICA/B Ab such as the use of drugs that can promote upregulation of MICA/B on tumor cells, blockers of sMICA/B shedding, synthetic lethality inducers that target PARP1, agonists of STING, drugs that induce ICD and molecules that target TAM. This evidence concerns the gene STING1 and neoplasm.